Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine in High-Risk T-ALL (GRAALL-2014/T)
NCT02619630Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2015
- Primary completion
- Dec 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nelarabine in acute lymphoblastic leukemia (ALL), sponsored by Assistance publique - Hôpitaux de Paris. Started Dec 2015; status: recruiting.
02
Drugs
nelarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02619630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619630.